Biodel Reports Second Quarter Fiscal Year 2015 Financial

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Biodel Reports Second Quarter Fiscal Year 2015 Financial Results

DANBURY, CT --(Marketwired - May 06, 2015) - Biodel Inc. ( NASDAQ : BIOD ) today reported financial results for the second fiscal quarter ended March 31, 2015.

Portfolio highlights since last fiscal quarter:

  • Announced positive clinical data from Study 6-101 demonstrating that administration of the formulation designed for use in the Glucagon Emergency Management (GEM) device results in glucagon exposure and glucose response that met standard bioequivalence criteria when compared to marketed glucagon
  • Announced results from a formative human factors study of its GEM device demonstrating a substantial improvement in ease of use and successful delivery of the full dose, as well as a reduction in dosing errors when compared to commercially available glucagon kits
  • Successfully completed a public offering, which generated approximately $32.1 million in net proceeds, including proceeds from the exercise of the over-allotment option
  • Received acceptance of 5 abstracts for presentation at the 2015 American Diabetes Association Scientific sessions. Four abstracts are on BIOD-531 and one is on the GEM program

Dr. Errol De Souza, president and chief executive officer of Biodel, stated: "This has been an extremely productive quarter for Biodel. With the exciting data from the recent clinical and human factor studies reported in the GEM program over the past two months and the continued progress made in the BIOD-531 program, coupled with our recent public offering, we are positioned to transition Biodel over the next 12 to 18 months to a later stage product development company with a diversified portfolio and significant potential to build shareholder value."

Second Quarter Financial Results

Biodel reported a net loss of $4.4 million and $9.0 million, or $0.18 and $0.40 per share for the quarter and six month periods ended March 31, 2015, respectively. These results compare to a net loss of $6.2 million and $8.6 million, or $0.29 and $0.41 per share for the quarter and six month periods ended March 31, 2014, respectively.

Biodel did not recognize any revenue during the quarter and six month periods ended March 31, 2015 or 2014.

At March 31, 2015, Biodel had cash and cash equivalents of $17.8 million and 24.6 million shares of common stock outstanding. After giving effect of the recent public offering, Biodel had cash and cash equivalents of $49.8 million and 62.1 million shares of common stock outstanding.

 
Biodel Inc. Condensed Consolidated Balance Sheets (in thousands, except share and per share amounts)
               
    September 30, 2014       March 31, 2015  
            (unaudited)  
ASSETS              
Current:              
  Cash and cash equivalents $ 24,588     $ 17,753  
  Prepaid and other assets   316       625  
                 
    Total current assets   24,904       18,378  
  Property and equipment, net   481       338  
  Intellectual property, net   40       38  
                 
      Total assets $ 25,425     $ 18,754  
               
LIABILITIES AND STOCKHOLDERS' EQUITY              
Current:              
  Accounts payable $ 172     $ 346  
  Accrued expenses:              
    Clinical trial expenses   214       399  
    Payroll and related   958       986  
    Accounting and legal fees   131       222  
    Other   141       146  
  Income taxes payable   -       3  
               
      Total current liabilities   1,616       2,102  
               
  Common stock warrant liability   1,014       302  
               
      Total liabilities   2,630       2,404  
Commitments              
  Stockholders' equity:              
  Convertible preferred stock, $.01 par value; 50,000,000 shares authorized; 1,950,000 and 1,909,410 issued and outstanding   19       19  
  Common stock, $.01 par value; 200,000,000 shares authorized; 23,079,543 and 24,620,322 issued and outstanding   231       246  
  Additional paid-in capital   252,104       254,687  
  Accumulated deficit   (229,559 )     (238,602 )
                 
      Total stockholders' equity   22,795       16,350  
                 
      Total liabilities and stockholders' equity $ 25,425     $ 18,754  
 
Biodel Inc. Condensed Consolidated Statements of Operations (in thousands, except share and per share amounts) (unaudited)
                               
    Three Months Ended March 31,       Six Months Ended March 31,  
    2014       2015       2014       2015  
Revenue $ -     $ -     $ -     $ -  
                               
Operating expenses:                              
  Research and development   4,257       2,917       7,998       6,324  
  Government grants   (207 )     -       (304 )     -  
  General and administrative   1,731       1,611       3,127       3,444  
                               
Total operating expenses   5,781       4,528       10,821       9,768  
Other (income) and expense:                              
  Interest and other income   (13 )     (7 )     (29 )     (16 )
  Adjustment to fair value of common stock warrant liability   426       (166 )     (2,161 )     (712 )
                               
Loss before tax provision   (6,194 )     (4,355 )     (8,631 )     (9,040 )
Tax provision   4       1       9       3  
                               
Net loss   (6,198 )     (4,356 )     (8,640 )     (9,043 )
                               
                               
Net loss per share - basic and diluted $ (0.29 )   $ (0.18 )   $ (0.41 )   $ (0.40 )
                               
Weighted average shares outstanding - basic and diluted   21,083,237       24,369,246       21,078,404       22,809,903  
                               

Conference Call and Webcast Information

Biodel's senior management will host a conference call on May 6, 2015 beginning at 5:00 p.m. Eastern Time to discuss these results and provide a company update. Live audio of the conference call will be available to investors, members of the news media and the general public by dialing +1 (877) 407-7181 (United States) or +1 (201) 689-8047 (international). To access the call by live audio webcast, please log on to the investor section of the company's website at www.biodel.com . An archived version of the audio webcast will be available on Biodel's website. Interested parties may also access an audio replay by dialing (877) 660-6853 (US) (201) 612-7415 (International) and entering conference ID number 13588552.

About Biodel Inc.

Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes that may be safer, more effective and more convenient for patients. Biodel's product candidates are developed by applying proprietary technologies to existing drugs in order to improve their therapeutic profiles. More information about Biodel is available at  www.biodel.com .

Safe-Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements about future activities related to the clinical development plans for Biodel's product candidates, potential timing, design and outcomes of clinical trials and Biodel's ability to develop and commercialize its product candidates. Forward-looking statements represent Biodel's management's judgment regarding future events. All statements, other than statements of historical facts, including statements regarding Biodel's strategy, future operations, future clinical trial results, future financial position, future revenues, projected costs, prospects, plans and objectives of management are forward-looking statements. The words "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Biodel's forward-looking statements are subject to a number of known and unknown risks and uncertainties that could cause actual results, performance or achievements to differ materially from those described or implied in the forward-looking statements, including, but not limited to, the progress, timing or success of Biodel's research and development and clinical programs for Biodel's product candidates; Biodel's ability to conduct the development work necessary to finalize the formulation and design of Biodel's auto-reconstitution glucagon rescue product candidate, as well as the preclinical studies, clinical trials and manufacturing activities necessary to support the filing of a new drug application, or NDA, to the U.S. Food and Drug Administration, or FDA, for that product candidate; Biodel's ability to engage a strategic partner in the further development of Biodel's prandial ultra-rapid-acting insulin formulations, including BIOD-531, which uses regular human insulin, or RHI, as the active pharmaceutical ingredient, and Biodel's insulin analog-based formulations; the success of Biodel's formulation development work to improve the stability of Biodel's newer ultra-rapid-acting insulin analog-based formulations while maintaining the pharmacokinetic and injection site toleration characteristics associated with earlier formulations; the results of Biodel's real-time stability programs for Biodel's RHI-, insulin analog- and glucagon-based product candidates, including the reproducibility of earlier, smaller scale, stability studies and Biodel's ability to accurately project long term stability on the basis of accelerated testing; Biodel's ability to accurately anticipate technical challenges that the company may face in the development of Biodel's ultra-rapid-acting RHI- and insulin analog-based product candidates or Biodel's glucagon rescue product candidates; Biodel's ability to secure approval by the FDA for Biodel's product candidates under Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act; Biodel's ability to enter into collaboration arrangements for the commercialization of Biodel's product candidates and the success or failure of any such collaborations into which the company enters, or Biodel's ability to commercialize its product candidates on its own; Biodel's ability to enforce Biodel's patents for Biodel's product candidates and Biodel's ability to secure additional patents for Biodel's product candidates; and other factors identified in our most recent annual report on Form 10-K for the fiscal year ended September 30, 2014 and other subsequent filings with the Securities and Exchange Commission. The company disclaims any obligation to update any forward-looking statements as a result of events occurring after the date of this press release.

BIOD-G

Source: Biodel, Inc.

CONTACT: Clayton Robertson Trout Group +1 (646) 378 2964

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 248

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 375

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 312

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 299

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 530

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 389

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 386

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 527

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 666

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading

Top 5 Most Recently Viewed Articles

Forecast Reveals Growth Surge in Healthcare IT by $199 Billion

Updated Category News Views 121

Growth Forecast for Healthcare IT Market The healthcare IT market is poised for substantial growth, projected to rise by USD 199.8 billion from 2024 to 2028. This growth is primarily fueled by an increasing emphasis on service quality and operational efficiency, alongside advancements in artificial intelligence (AI) technologies that are transforming healthcare practices....

Continue Reading
Revolutionizing Painting: Rust-Oleum's Low Odor Spray Paint

Updated Category News Views 197

Transform Your Painting Experience with Rust-Oleum For many, the smell of traditional spray paint can be quite off-putting, often making the creative process less enjoyable. Thankfully, Rust-Oleum has taken a bold step towards addressing this issue by introducing a product that fundamentally shifts the painting experience. Introducing Low Odor Premium Spray Paint...

Continue Reading
Banking Academy and Vantage Foundation Unite for Financial Growth

Updated Category News Views 116

Strategic Partnership Between Banking Academy and Vantage Foundation In an exciting development for financial education, the Banking Academy of Vietnam (BAV) and Vantage Foundation have formed a significant strategic partnership. This collaboration was marked by the signing of a Memorandum of Understanding (MoU) at the Banking Academy's headquarters, symbolizing a...

Continue Reading
Investor Alert: Dave Inc. Faces Class Action Investigation

Updated Category News Views 296

Understanding the Current Situation of Dave Inc. Recently, there has been a growing concern among shareholders of Dave Inc. (NASDAQ: DAVE) regarding potential misleading information disseminated by the company. This has prompted Rosen Law Firm, a respected advocate for investor rights, to initiate an investigation aimed at uncovering possible securities claims. As this...

Continue Reading
Exploring the Rise of GE Aerospace: Investors' Perspective

Updated Category News Views 289

Understanding GE Aerospace's Growth GE Aerospace has shown remarkable performance over recent years, outpacing the overall market significantly. For the last five years, it has delivered an astounding 38.48% return on an annualized basis, reflecting an impressive average annual return of 52.35%. This optimistic trend has contributed to its current market capitalization,...

Continue Reading